You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/64649
Title: 
PREVENCAO DE TROMBOFLEBITES PELO USO DE HEPARINA EM PACIENTES TRATADOS COM ANFOTERICINA B
Other Titles: 
Prevention of thrombophlebitis with the use of heparin in patients treated with amphotericin B
Author(s): 
Institution: 
Universidade Estadual Paulista (UNESP)
ISSN: 
0210-5187
Abstract: 
The authors studied the incidence of thrombophlebitis in 41 patients treated intravenously with amphotericin B. The patients were divided in two different group: Group 1: patients treated with amphotericin B and hydrocortisone with heparin (1000 UI); Group 2: patients treated with amphotericin B and hydrocortisone. The results showed 23.81% of incidence of thrombophlebitis in Group 1 and 90% in Group 2. Thrombophlebitis in Group 1 ranged from mild to moderate without any change during the drug therapy. In Group 2, the incidence was 66.67% and the thrombophlebitis were severe being necessary the withdrawn of the drugs in 35.0% of the cases. We concluded that heparin, in low doses, in association with amphotericin B, was an efficient drug preventing or reducing the development of thrombophlebitis.
Issue Date: 
1-Dec-1995
Citation: 
Medicina Cutanea Ibero-Latino-Americana, v. 23, n. 8, p. 377-382, 1995.
Time Duration: 
377-382
Keywords: 
  • amphotericin B
  • heparin
  • thrombophlebitis
  • amphotericin b
  • hydrocortisone
  • adolescent
  • adult
  • aged
  • clinical article
  • clinical trial
  • controlled clinical trial
  • controlled study
  • drug effect
  • female
  • human
  • incidence
  • male
Source: 
http://cat.inist.fr/?aModele=afficheN&cpsidt=2955274
URI: 
Access Rights: 
Acesso restrito
Type: 
outro
Source:
http://repositorio.unesp.br/handle/11449/64649
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.